Invion Ltd. · ASX:IVX
Invion — Shareholder Meeting (November 2022)
18 slides from Invion's shareholder meeting presentation, Nov 17, 2022
Slide 1: Annual General Meeting November 2022
For personal use only ANNUAL GENERAL MEETING November 2022
Slide 2: CEO AGM Presentation: Laying the groundwork for an exciting 2023
For personal use only CEO AGM PRESENTATION Laying the groundwork for an exciting 2023
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Key Achievements: Highlights Over the Past Year
KEY ACHIEVEMENTS HIGHLIGHTS OVER THE PAST YEAR For personal use only Agreement with IDT for Cancer Research Partners: Cancer GMP manufacture ahead of clinical trials (Nov) Effective against International Anal Cancer SCC patent extends IP in vitro protection for (Sep) INV043 Significantly PhotosoftTM
Slide 5: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 PATHWAY TO PARTICIPATE IN A US$271B MARKET OPPORTUNITY1 For personal use only Proof-of-Concept studies of lead candidate INV043 has been shown to: Selectively absorbed by cancer cells and not healthy tissue Effective in regressing multiple types of cancer in vivo Ca
Slide 6: Improved API: INV043 Key Characteristics
IMPROVED API: INV043 KEY CHARACTERISTICS* For personal use only Active against multiple cancers Highly potent and selective INV043 activity against multiple cancer cell types • INV043 successfully regressed • ~600x greater photoxicity established T-cell lymphoma, than Talaporfin sodium (a triple neg
Slide 7: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only Treatment with established tumours (INV043 with light) • INV043 was injected intratumorally (0.1mg/kg) • 16 hours later, illuminated with red light • No anaesthesia required, no adverse effects obse
Slide 8: Proof of Concept: Primary Tumour Pilot Study
PROOF OF CONCEPT: PRIMARY TUMOUR PILOT STUDY REGRESSION AND PROTECTIVE IMMUNITY For personal use only • Triple Negative Breast Cancer (TNBC) is a hard-to-treat cancer resistant to most chemotherapies • Proof of Concept (PoC) pilot showed complete regression of TNBC in vivo following INV043 treatment
Slide 9: Anal Cancer SCC: Promising Results Against New Cancer Class
ANAL CANCER SCC PROMISING RESULTS AGAINST NEW CANCER CLASS* For personal use only Cytotoxicity data of human anal SCC cells lines In vitro study showed INV043’s effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers Most anal cancers are SCCs
Slide 10: Proof of Concept: Immune Checkpoint Inhibitors Combination Therapy
PROOF OF CONCEPT: IMMUNE CHECKPOINT INHIBITORS (ICI) COMBINATION THERAPY FOR PARTICIPATION IN THIS US$140B MARKET1 (BY 2030) For personal use only • Immune checkpoint inhibitors are widely used for the treatment of lung cancer and melanoma. However, ICI treatments are typically only effective on a s
Slide 11: Infectious Diseases
For personal use only Infectious Diseases Exploring the potential applications of PhotosoftTM
Slide 12: Broad-Spectrum Anti-Microbial Potential
BROAD-SPECTRUM ANTI-MICROBIAL POTENTIAL INFECTIOUS DISEASES: EFFECTIVE AGAINST VIRUSES, BACTERIA AND FUNGI IN VITRO For personal use only “Antimicrobial resistance (AMR) is one of the top 10 threats facing humanity” World Health Organisation1 Leading Institutions: Viroclinics conducted virus “ tests
Slide 13: Effective Against SARS-CoV-2 In Vitro
EFFECTIVE AGAINST SARS-CoV-2 IN VITRO ANTIVIRAL ACTIVITY AGAINST DELTA AND OMICRON VARIANTS For personal use only SARS-CoV-2: Delta Selected PhotosoftTM Compounds vs. Remdesivir 100 Nine out of ten PhotosoftTM compounds tested displayed antiviral activity against both Delta 80 % Inhibition and Omicr
Slide 14: Effective Against Zika and Dengue In Vitro
EFFECTIVE AGAINST ZIKA AND DENGUE IN VITRO ANTIVIRAL ACTIVITY AGAINST ZIKA AND DENGUE For personal use only Zika Dengue Inhibition: PhotosoftTM compound vs Monensin1 Inhibition: Selected PhotosoftTM Compounds vs Monensin1 100 100 90 90 Percentage (%) inhibition 80 80 70 70 % Inhibition 60 60 50 50 4
Slide 15: Effective Against Bacteria and Fungi
EFFECTIVE AGAINST BACTERIA AND FUNGI MRSA SUPERBUG, E.COLI BACTERIA & CANDIDA ALBICANS FUNGUS For personal use only Broad Spectrum Activity: Minimum Inhibition Several PhotosoftTM compounds showed Concentration (MIC50) of Selected Photosoft Compound following exposure to light for 5 minutes activi
Slide 16: The Way Forward: Multiple Catalysts and Milestones
THE WAY FORWARD MULTIPLE CATALYSTS AND MILESTONES For personal use only Australia • Proof of Concept (PoC) Building on in vivo work further demonstrating both safety and efficacy profiles • Pre-clinical Preparations: Building foundations for clinical trials in multiple indications and internationall
Slide 17: Management Team
MANAGEMENT TEAM THE RIGHT EXPERTISE FOR SUCCESS For personal use only THIAN CHEW MELANIE LEYDIN EXECUTIVE CHAIRMAN & CEO CFO • Managing Partner, Polar Ventures • 25+ years in accounting profession • Executive Director, Goldman Sachs • Partner, Vistra • Director, KPMG Consulting, Senior Manager KPMG
Slide 18: Summary
SUMMARY For personal use only Cancer - Promising Results: Infectious Diseases – Early Findings: Total tumour regression, In vitro effectiveness against multiple immune response, potential ICI viruses & bacteria including SARS-CoV- combination therapies 2 (Delta and Omicron) and MRSA Cancer - Clinica